Lydia Scarfo, MD, Vita-Salute San Raffaele University, Milan, Italy, talks about the combination of ibrutinib and venetoclax and tailoring chronic lymphocytic leukemia (CLL) treatment based on response. Dr Scarfo goes on to discuss the main challenges being faced in CLL. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

свернуть